Seattle biotech BrainChild Bio has raised $116 million to advance an experimental CAR T cell therapy for DIPG, a rare and deadly brain tumor that primarily affects young children. The company is building on technology developed at Seattle Children’s and is also developing CAR T therapies for other pediatric and adult brain tumors. Read More
